Eris Lifesciences shares rise on Natco tie-up for Semaglutide launch

Natco has received approval from the Central Drugs Standard Control Organisation to manufacture the generic version of Semaglutide, with the launch expected in March 2026.

Leave a Reply

Your email address will not be published. Required fields are marked *